Psilocybin vs Escitalopram for Depression
The Carlat Psychiatry Report, Volume 19, Number 9, September 2021
Michael Posternak, MD.
Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Psilocybin is inching its way toward FDA approval in depression, but will this trial from the New England Journal of Medicine help it along or set it back?